https://orcid.org/0000-0002-4873-8130
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Article highlights
Immunotherapies may present a novel approach to help address the evolving opioid overdose crisis
Preclinical data suggest that opioid vaccines and monoclonal antibodies have therapeutic potential
More research, specifically in humans, is needed to demonstrate the efficacy and safety of immunotherapies for opioid use disorder and better understand potential implementation barriers
List of Abbreviations
FDA Food and Drug Administration
OUD Opioid Use Disorder
Declaration of interests
Within the past three years, JD Jones received compensation (in the form of partial salary support) and has served as a paid consultant to Alkermes and the World Health Organization. Within the past three years, SD Comer has received research funding from Alkermes, BioXcel Therapeutics, Corbus, Go Medical, Intra-cellular Therapies, Janssen, and Lyndra. SD Comer has also consulted for: Alkermes, Clinilabs, Opiant, and Otsuka, and she has received honoraria from the World Health Organization. SD. Comer is also the recipient of NIH funding to study opioid vaccines and monoclonal antibodies. M Pravetoni has filed patents disclosing the composition and methods of use of vaccines and monoclonal antibodies for substance use disorders. Dr. Pravetoni is also the recipient of NIH funding to study opioid vaccines and monoclonal antibodies.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.